Comparative Pharmacology
Head-to-head clinical analysis: FYREMADEL versus KADIAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FYREMADEL versus KADIAN.
FYREMADEL vs KADIAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FYREMADEL is a GLP-1 receptor agonist that activates GLP-1 receptors, increasing insulin secretion and decreasing glucagon secretion in a glucose-dependent manner, and slows gastric emptying.
Mu-opioid receptor agonist; modulates pain perception and emotional response to pain.
100 mg orally twice daily.
20-100 mg orally every 12 hours; titration based on pain severity and prior opioid exposure.
None Documented
None Documented
Terminal half-life: 12 hours (range 8–16 h) in healthy adults; prolonged in hepatic impairment.
Terminal elimination half-life of morphine: 2–4 hours; KADIAN extended-release formulation: effective half-life ~12 hours due to prolonged absorption, dosing q12h or q24h
Renal: 60% unchanged; Biliary/Fecal: 30% as metabolites; 10% other.
Renal: primarily as morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G); ~90% of total elimination is renal, with 10% biliary/fecal
Category C
Category C
Opioid Analgesic
Opioid Analgesic